Tigecycline MRA so that blood volume decreases

so that blood volume decreases and urine volume increases

orally available inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2

Nepafenac inhibits prostaglandin synthesis in the iris/ciliary body (85-95%) and the retina/choroid (55%) in rabbits

LY2365109 is a selective inhibitor of GlyT1 with IC50 of 158 nM

Tigecycline MRA so that blood volume decreasesTigecycline is a glycylcycline antibiotic developed by Francis Tally and marketed by Wyeth under the brand name Tygacil. It was given a U. S. Food and Drug Administration (FDA) fast track approval and was approved on June 17, 2005. It was developed in response to the growing prevalence of antibiotic resistance in bacteria such as Staphylococcus aureus and Acinetobacter baumannii. The New Delhi metallo Lactamase multidrug resistant Enterobacteriaceae